Advertisement
ACET vs VIVS
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACET is a Hold and VIVS is a Hold.
ACET sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for ACET moved below the 200-day moving average on October 21, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACET declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for ACET entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Moving Average Convergence Divergence (MACD) for ACET just turned positive on November 04, 2026. Looking at past instances where ACET's MACD turned positive, the stock continued to rise in 35 of 42 cases over the following month. The odds of a continued upward trend are 83%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.238) is normal, around the industry mean (3.498). P/E Ratio (-0.293) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. ACET’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACET’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
VIVS's RSI Oscillator climbs out of oversold territory
The RSI Indicator for VIVS moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 44 similar instances when the indicator left oversold territory. In 38 of the 44 cases the stock moved higher. This puts the odds of a move higher at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 53 of 67 cases where VIVS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Momentum Indicator moved above the 0 level on November 11, 2026. You may want to consider a long position or call options on VIVS as a result. In 71 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
Following a +2.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where VIVS advanced for three days, in 158 of 202 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
VIVS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VIVS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for VIVS entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.808) is normal, around the industry mean (3.498). P/E Ratio (-0.032) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (7.446) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. VIVS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VIVS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
ACET | VIVS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 51 | 28 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 47 Fair valued | 35 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 100 | |
PRICE GROWTH RATING 1..100 | 94 | 93 | |
P/E GROWTH RATING 1..100 | 8 | 98 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
VIVS's Valuation (35) in the Biotechnology industry is in the same range as ACET (47) in the Medical Distributors industry. This means that VIVS’s stock grew similarly to ACET’s over the last 12 months.
VIVS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ACET (100) in the Medical Distributors industry. This means that VIVS’s stock grew similarly to ACET’s over the last 12 months.
ACET's SMR Rating (98) in the Medical Distributors industry is in the same range as VIVS (100) in the Biotechnology industry. This means that ACET’s stock grew similarly to VIVS’s over the last 12 months.
VIVS's Price Growth Rating (93) in the Biotechnology industry is in the same range as ACET (94) in the Medical Distributors industry. This means that VIVS’s stock grew similarly to ACET’s over the last 12 months.
ACET's P/E Growth Rating (8) in the Medical Distributors industry is significantly better than the same rating for VIVS (98) in the Biotechnology industry. This means that ACET’s stock grew significantly faster than VIVS’s over the last 12 months.
| ACET | VIVS | |
|---|---|---|
| RSI ODDS (%) | 6 days ago 85% | 1 day ago 86% |
| Stochastic ODDS (%) | N/A | 1 day ago 79% |
| Momentum ODDS (%) | N/A | 1 day ago 76% |
| MACD ODDS (%) | 1 day ago 83% | N/A |
| TrendWeek ODDS (%) | 1 day ago 88% | 1 day ago 77% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| Advances ODDS (%) | N/A | 3 days ago 78% |
| Declines ODDS (%) | 7 days ago 88% | 9 days ago 90% |
| BollingerBands ODDS (%) | N/A | 1 day ago 84% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ACET’s FA Score shows that 1 FA rating(s) are green while VIVS’s FA Score has 0 green FA rating(s).
- ACET’s FA Score: 1 green, 4 red.
- VIVS’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ACET’s TA Score shows that 2 TA indicator(s) are bullish while VIVS’s TA Score has 5 bullish TA indicator(s).
- ACET’s TA Score: 2 bullish, 3 bearish.
- VIVS’s TA Score: 5 bullish, 2 bearish.
Price Growth
ACET (@Biotechnology) experienced а -5.36% price change this week, while VIVS (@Biotechnology) price change was +1.58% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
ACET is expected to report earnings on Mar 17, 2027.
VIVS is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ACET and
Correlation & Price change
A.I.dvisor indicates that over the last year, ACET has been loosely correlated with VIR. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ACET jumps, then VIR could also see price increases.
| Ticker / NAME | Correlation To ACET | 1D Price Change % | ||
|---|---|---|---|---|
| ACET | 100% | -0.33% | ||
| VIR - ACET | 42% Loosely correlated | -0.15% | ||
| OGI - ACET | 41% Loosely correlated | +0.15% | ||
| RXRX - ACET | 41% Loosely correlated | +1.13% | ||
| IMTX - ACET | 38% Loosely correlated | +4.21% | ||
| COYA - ACET | 38% Loosely correlated | +1.58% | ||
More | ||||
VIVS and
Correlation & Price change
A.I.dvisor indicates that over the last year, VIVS has been loosely correlated with DMRA. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if VIVS jumps, then DMRA could also see price increases.
| Ticker / NAME | Correlation To VIVS | 1D Price Change % | ||
|---|---|---|---|---|
| VIVS | 100% | +19.47% | ||
| DMRA - VIVS | 38% Loosely correlated | -3.73% | ||
| ORMP - VIVS | 37% Loosely correlated | +4.03% | ||
| AEON - VIVS | 27% Poorly correlated | -4.41% | ||
| ACET - VIVS | 27% Poorly correlated | -0.33% | ||
| KRRO - VIVS | 26% Poorly correlated | -8.39% | ||
More | ||||